Roche wins FDA approval for immunotherapy cocktail against lung cancer

Roche wins FDA approval for immunotherapy cocktail against lung cancer

Roche's Tecentriq immunotherapy mixed with chemotherapy won U.S. approval as an initial treatment for a form of lung cancer as the Swiss drugmaker seeks to establish its alternative to drugs from Merck and Bristol-Myers Squibb.

FILE PHOTO: Logo of Swiss drugmaker Roche is seen at its headquarters in Basel
FILE PHOTO: The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland February 1, 2018. REUTERS/Arnd Wiegmann/File Photo

ZURICH: Roche's Tecentriq immunotherapy mixed with chemotherapy won U.S. approval as an initial treatment for a form of lung cancer as the Swiss drugmaker seeks to establish its alternative to drugs from Merck and Bristol-Myers Squibb.

The U.S. Food and Drug Administration approved Tecentriq mixed with Celgene's Abraxane and carboplatin chemotherapy to treat metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations, Roche said on Wednesday.

(Reporting by John Miller; editing by Thomas Seythal)

Source: Reuters

Bookmark